Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge ADVISES Hexatronic IN CONNECTION WITH THE ACQUISITION OF Ericsson’s TELECoM CABLES BUSINESS IN Hudiksvall
Mandate

Vinge ADVISES Hexatronic IN CONNECTION WITH THE ACQUISITION OF Ericsson’s TELECoM CABLES BUSINESS IN Hudiksvall

November 04, 2013

Vinge has advised Hexatronic Cable and Interconnect Systems AB, a wholly owned subsidiary of Hexatronic Scandinavia AB (publ), in connection with the acquisition of Ericsson’s fibre and sea cable business in Hudiksvall. In 2013, the business has a pro forma turnover of SEK 350 million and in connection with closing approximately 85 employees will be transferred for fibre production purposes and approximately 30 employees will be transferred during a transitional period for copper cable production purposes.

Vinge’s team consisted of, among others, partner Anders Strid and associates Anna Siesing (M&A and employment), Anna Palmérus (competition) and Ingrid Johansson (commercial property)

ScandCap, through Oskar Säfström, acted as Hexatronic’s financial advisers.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025